The current status of hormone treatment for prostate cancer patients in Korean real-world practice:a multi-institutional observational study

作     者：Jung Kwon Kim Jung Jun Kim Taek Won Gang Tae Kyun Kwon Hong Sup Kim Seung Chui Park Jae-Shin Park Jong-Yeon Park Seok Joong Yoon Youn-Soo Jeon Jin Seon Cho Kwan Joong Joo Sung-Hoo Hong Seok-Soo Byun the Korean Urological Oncology Society 

作者机构：Department of UrologySeoul National University Bundang HospitalSeongnam 13620Korea Department of UrologyHallym University Sacred Heart HospitalAnyang 14068Korea Department of UrologyKangbuk Samsung HospitalSeoul 03181Korea Department of UrologySeoul St.Mary HospitalSeoul 06591Korea 不详 Department of UrologyChonnam National University HospitalGwangju 61469Korea School of MedicineKyungpook National University Medical CenterDaegu 41404Korea Department of UrologyKonkuk University Medical CenterSeoul 05080Korea Department of UrologyWonkwang University HospitalIksan 54538Korea Department of UrologyDaegu Catholic University Medical CenterDaegu 41911Korea Department of UrologyUlsan UniversityGangneung Asan HospitalGangneung 25440Korea Department of UrologyChungbuk National University HospitalCheongju 28644Korea Department of UrologySoonchunhyang University HospitalCheonan 31151Korea 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2019年第21卷第2期

页      面：115-120页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 10[医学] 

基　　金：supported by a grant from the Korean Urological Oncology Society 2014 research fund 

主　　题：efficacy hormonal treatment Korean population prostate cancer safety trend 

摘      要：We aimed to evaluate the current nationwide trend,efficacy,safety,and quality of life(QoL)profiles of hormone treatment in real-world practice settings for prostate cancer(PCa)patients in Korea.A total of 292 men with any biopsy-proven PCa(TanyNanyMany)from 12 institutions in Korea were included in this multi-institutional,observational study of prospectively collected data.All luteinizing hormone-releasing hormone(LHRH)agonists were allowed to be investigational drugs.Efficacy was defined as(1)the rate of castration(serum testosterone≤50 ng dl^-1)at 4-week visit and(2)breakthrough(serum testosterone50 ng dl^-1 after castration).Safety assessments included routine examinations for potential adverse events,laboratory tests,blood pressure,body weight,and bone min era I density(BMD,at baseli ne and at the last follow-up visit).QoL was assessed using the Expa nded Prostate Cancer Index Composite-26(EPIC-26).The most comm on initial therapeutic regimen was LHRH agonist with an ti-androge n(78.0%),and the most commonly used LHRH agonist for combination and mono therapy was leuprolide(64.0%for combi natio n and 58.0%for monotherapy).The castration and breakthrough rates were 78.4%and 6.6%,respectively.The laboratory results related to dyslipidemia worsened after 4 weeks of hormone treatment.In addition,the mean BMD T-score was significantly lower at the last follow-up(mean:-1.950)compared to baseline(mean:-0.195).The mean total EPIC-26 score decreased from 84.8(standard deviation[s.d.]:12.2)to 78.3(s.d.:8.1),with significant deterioration only in the urinary domain(mean:23.5 at baseli ne and 21.9 at the 4-week visit).These findi ngs dem on strate the n ationwide trend of current practice setti ngs in hormone treatment for PCa in Korea.